Abstract |
Over the past 10 years, cancer immunotherapy has made significant progress in multiple cancer types and has been gradually been applied to clinical cancer care, in which the programmed cell death protein-1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway is one of the most attractive targets. Compared with traditional therapies, the emerging PD-1/PD-L1 blockade immunotherapy exhibited more satisfactory curative effects and lower toxicity for patients with advanced head and neck squamous cell carcinoma ( HNSCC). This review analyzes the expression characteristics and clinical significance of PD-1/PD-L1 in HNSCC, the immunosuppressive roles of tumor cell and stromal cell expressing PD-1/PD-L1 in this disease, and presents the development landscape of PD-1/ PD-L1 inhibitors, which may provide new curative alternatives for recurrent or metastatic HNSCC.
|
Authors | Xin-Wei Qiao, Jian Jiang, Xin Pang, Mei-Chang Huang, Ya-Jie Tang, Xin-Hua Liang, Ya-Ling Tang |
Journal | Frontiers in immunology
(Front Immunol)
Vol. 11
Pg. 1721
( 2020)
ISSN: 1664-3224 [Electronic] Switzerland |
PMID | 33072064
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Copyright | Copyright © 2020 Qiao, Jiang, Pang, Huang, Tang, Liang and Tang. |
Chemical References |
- Antineoplastic Agents, Immunological
- B7-H1 Antigen
- CD274 protein, human
- Immune Checkpoint Inhibitors
- PDCD1 protein, human
- Programmed Cell Death 1 Receptor
|
Topics |
- Animals
- Antineoplastic Agents, Immunological
(therapeutic use)
- B7-H1 Antigen
(antagonists & inhibitors, immunology, metabolism)
- Head and Neck Neoplasms
(drug therapy, immunology, metabolism, pathology)
- Humans
- Immune Checkpoint Inhibitors
(therapeutic use)
- Immunotherapy
- Programmed Cell Death 1 Receptor
(antagonists & inhibitors, immunology, metabolism)
- Signal Transduction
- Squamous Cell Carcinoma of Head and Neck
(drug therapy, immunology, metabolism, pathology)
- Tumor Microenvironment
|